COVID-19: First Do No Harm.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs.Clinical and experimental medicine · 2024
   Pooled it
2. Convalescent plasma for SARS-CoV-2 infection: win or learn.The European respiratory journal · 2022
   Article
3. "MATH+" Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale.Journal of clinical medicine research · 2022
   Review
4. Uses of equipoise in discussions of the ethics of randomized controlled trials of COVID-19 therapies.BMC medical ethics · 2021
   Article
5. Variation in COVID-19 characteristics, treatment and outcomes in Michigan: an observational study in 32 hospitals.BMJ open · 2021
   Observational
6. COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes.Annals of the American Thoracic Society · 2021
   Observational
7. Update in COVID-19 2020.American journal of respiratory and critical care medicine · 2021
   Review
8. Severe COVID-19 pneumonia in Piacenza, Italy - A cohort study of the first pandemic wave.Journal of infection and public health · 2021
   Article
9. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.The Journal of allergy and clinical immunology · 2021
   Observational
10. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.Infectious diseases and therapy · 2020
    Article
11. Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium.Anaesthesia, critical care & pain medicine · 2020
    Review
12. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.Journal of autoimmunity · 2020
    Observational
13. Integrating the evidence: confronting the COVID-19 elephant.Intensive care medicine · 2020
    Article
14. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.Infectious diseases and therapy · 2020
    Article
15. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.Annals of the American Thoracic Society · 2020
    Article
16. Quality of evidence supporting Surviving Sepsis Campaign Recommendations.Anaesthesia, critical care & pain medicine · 2020
    Article
17. In defence of extrapolation but not improvisation in SARS-CoV-2 lung disease.Breathe (Sheffield, England) · 2020
    Article
18. Poor quality research and clinical practice during COVID-19.Breathe (Sheffield, England) · 2020
    Article

Corrections and comments

• Comment on
  Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study.2020
• Comment on
  COVID-19 with Different Severities: A Multicenter Study of Clinical Features.2020

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as